Cancer Family
Malignant Respiratory System Neoplasm
CI-CAN-00000249Explore in graph →
2,648 active trials51 approved drugs619 evidence items
- NCIt
- C4571
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000249Explore in graph →
Clinical trials
11,125 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,490)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04201990 | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer(CCA-MPLC) | unknown | Phase 1 / Phase 2 | 20 | ShiYue LiOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT04199559 | Evaluating Combination Therapy Using Autologous Dendritic Cells Pulsed With Antigen Peptides and Nivolumab for Subjects With Advanced Non-Small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 16, 2019 |
| clinicaltrials |
| NCT03638206 | Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies | unknown | Phase 1 / Phase 2 | 73 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Dec 11, 2019 | clinicaltrials |
| NCT04182698 | Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC | unknown | Phase 1 / Phase 2 | 90 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04175158 | Clinical Trial in Chinese Healthy Volunteers of GB222 | unknown | Phase 1 | 84 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02367443 | Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC | unknown | Phase 1 / Phase 2 | 92 | Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology CentreOTHER | 1 | Nov 6, 2019 | clinicaltrials |
| NCT03910127 | Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC） | unknown | Phase 1 | 90 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Oct 30, 2019 | clinicaltrials |
| NCT02836834 | Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors | unknown | Phase 1 | 33 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT04133337 | Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC | unknown | Phase 1 / Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT03396497 | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | unknown | Phase 1 | 17 | Lycera Corp.INDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT04059874 | Treatment of Non-small Cell Lung Cancer With PD-1 Monoclonal Antibody Combined With Donafenib Toluene Sulfonate | unknown | Phase 1 | 20 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT03983928 | Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer | unknown | Phase 1 / Phase 2 | 30 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03726736 | Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC(ACWDVDFPTAN) | unknown | Phase 1 / Phase 2 | 97 | Yong FangOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT03971214 | PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer(PICARES) | unknown | Phase 1 | 6 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT03902470 | Awake Thoracic Epidural Anaesthesia Versus General Anesthesia for Video Assisted Thoracoscopic Surgery | unknown | Phase 1 | 60 | Assiut UniversityOTHER | 0 | Apr 4, 2019 | clinicaltrials |
| NCT03903887 | A Study of Anti-PD1 Antibody-activated TILs in Non-small Cell Lung Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 4, 2019 | clinicaltrials |
| NCT03871205 | Neoantigen-primed DC Vaccines Therapy for Refractory Lung Cancer | unknown | Phase 1 | 30 | Shenzhen People's HospitalOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT03603262 | Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC | unknown | Phase 1 | 85 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT03029273 | NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC | unknown | Phase 1 | 20 | Guangzhou Institute of Respiratory DiseaseOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT03799094 | Vitamin C and Tyrosine Kinase Inhibitor in Lung Cancer Patients With Epidermal Growth Factor Receptor Mutations | unknown | Phase 1 / Phase 2 | 150 | Clifford Hospital, Guangzhou, ChinaOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT03751592 | Phase Ib/IIa Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Advanced Lung Cancer | unknown | Phase 1 / Phase 2 | 144 | Sichuan J.Z. Bio-chemical Science and Technology Development Co., LtdINDUSTRY | 1 | Nov 26, 2018 | clinicaltrials |
| NCT03050047 | A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 15 | BiocadINDUSTRY | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02450656 | Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer(M14AFS) | unknown | Phase 1 / Phase 2 | 320 | The Netherlands Cancer InstituteOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT03636685 | Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | unknown | Phase 1 / Phase 2 | 60 | Chinese Academy of Medical SciencesOTHER | 0 | Aug 17, 2018 | clinicaltrials |
| NCT03628521 | First-line Combination Treatment Based on Anlotinib | unknown | Phase 1 | 80 | Shanghai Chest HospitalOTHER | 1 | Aug 14, 2018 | clinicaltrials |
| NCT03601598 | A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC | unknown | Phase 1 / Phase 2 | 41 | Harbin Medical UniversityOTHER | 0 | Jul 26, 2018 | clinicaltrials |
| NCT03560362 | Postoperative Pain Control With Lipossomic Extended Release Bupivacaine | unknown | Phase 1 / Phase 2 | 50 | University of TennesseeOTHER | 1 | Jun 20, 2018 | clinicaltrials |
| NCT02956551 | Personalized DC Vaccine for Lung Cancer(SKLB1608) | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 31, 2018 | clinicaltrials |
| NCT03527251 | Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC(SEQUENCE) | unknown | Phase 1 | 10 | Sun Yat-sen UniversityOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT03525782 | Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC | unknown | Phase 1 / Phase 2 | 60 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02758587 | Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) | unknown | Phase 1 / Phase 2 | 59 | NHS Greater Glasgow and ClydeOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT03464032 | A Study of BCD-135 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | BiocadINDUSTRY | 1 | Mar 13, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03446911 | Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery | unknown | Phase 1 / Phase 2 | 20 | Amsterdam UMC, location VUmcOTHER | 0 | Feb 27, 2018 | clinicaltrials |
| NCT02151721 | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer(VICTORY-J) | unknown | Phase 1 | 12 | Kanazawa UniversityOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT03201146 | Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | unknown | Phase 1 / Phase 2 | 48 | West China HospitalOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT03198923 | Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer | unknown | Phase 1 | 30 | Wenxiang WangOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT03282435 | Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody | unknown | Phase 1 | 30 | Dalian UniversityOTHER | 0 | Sep 14, 2017 | clinicaltrials |
| NCT03205930 | Neo-MASCT Immunotherapy for Advanced NSCLC. | unknown | Phase 1 / Phase 2 | 20 | The First People's Hospital of LianyungangOTHER | 1 | Jul 5, 2017 | clinicaltrials |
| NCT02349724 | A Clinical Research of CAR T Cells Targeting CEA Positive Cancer | unknown | Phase 1 | 75 | Southwest Hospital, ChinaOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT02441972 | Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics | unknown | Phase 1 | 200 | Wuxi No. 4 People's HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT02695550 | Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer | unknown | Phase 1 | 40 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Mar 9, 2017 | clinicaltrials |
| NCT03057340 | The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells | unknown | Phase 1 | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT03050411 | Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer | unknown | Phase 1 | 30 | Peking University Third HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT02839954 | CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02587689 | Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor | unknown | Phase 1 / Phase 2 | 20 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 5, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Dec 17, 2019source: clinicaltrials